FDG-PET in addition to conventional work-up in non-small-cell lung cancer [10]

Journal of Clinical Oncology

Volumn 23, Issue 7, 2005, Pages 1591-

  van Tinteren, Harm ^a   Smit, Egbert F ^b   Hoekstra, Otto S ^b  

^a Integraal Kankercentrum Amsterdam   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER STAGING; CLINICAL TRIAL; CONSENSUS; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THORACOTOMY; LUNG TUMOR; NOTE; SCINTISCANNING;

CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 14944365660     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.201     Document Type: Letter

References (3)

1. Viney RC, Boyer MJ, King MT, et al: Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 22:2357-2362, 2004
2. van Tinteren H, Hoekstra OS, Smit EF, et al: Effectiveness of positron emission tomography in the pre-operative assessment of patients with suspected non-small cell lung cancer: The 'PLUS' multi-centre randomised trial. Lancet 359:1388-1393, 2002
3. Ettinger DS, Cox JD, Ginsberg RJ, et al: NCCN non-small-cell lung cancer practice guidelines: The National Comprehensive Cancer Network. Oncology (Huntingt) 10:81-111, 1996(suppl 11)